

Blood.
v. 102, no. 11, pt. 1 (Nov. 16 2003)
General Collection
W1 BL661
2003-11 24 09:51:13

bloo

JOURNAL OF
THE AMERICAN
SOCIETY OF
HEMATOLOGY

VOLUME 102
NUMBER 11
NOVEMBER 16, 2003

PART 1 OF 2 PARTS

American Society
of Hematology

Forty-fifth annual
meeting program
and abstracts

December 6-9, 2003



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

DOCKET
A L A R M

Find authenticated court documents without watermarks at docketalarm.com.

Blood, Journal of The American Society of Hematology (print ISSN 0006-4971, online ISSN 1528-0020), is published 25 times (in 2 volumes) per year by The American Society of Hematology (ASH), 1900 M Street, NW, Suite 200, Washington, DC 20036. Dates of issue are the 1st and the 15th of each month, except in November, when 3 issues are published. Printed in the United States of America. Periodicals postage paid at Washington, DC, and additional mailing offices.

Postmaster: Send change-of-address information to *Blood Journal*, PO Box 10812, Birmingham, AL 35202-0812.

Manuscript submissions

Consult the Author Guide printed in each issue of *Blood* (and posted on the web site at www.bloodjournal.org) before submitting your manuscript online at <http://blood.manuscriptcentral.com>.

2004 subscription rates

United States and possessions: *individual*, \$532; *institution*, \$960. **All other countries:** *individual*, \$747; *institution*, \$1155. There is no additional charge for surface delivery to any area outside the United States and possessions. For airmail delivery, add \$165 to your subscription price. *Blood* offers a reduced rate for students, interns, and residents who are in approved hematology or oncology programs: United States and possessions, \$244; all other countries, \$667. To qualify, supply your name, dates of study, and the signature of your academic advisor on institutional letterhead. Orders will be billed at the individual rate until proof of status is received.

Price for single/back issues: \$40/48. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability.

Pay-per-view: Full-text online access to all articles is free one year after publication. Nonsubscribers may purchase 24-hour access to the full text of any article published in the preceding 12 months through the pay-per-view option on the *Blood* website.

Subscription information, claims, and changes of address

Customer service for subscribers: 1-800-633-4931 (US and Canada); 1-205-995-1567 (outside US and Canada). Correspondence regarding subscriptions and changes of address should be addressed to *Blood Journal* Subscription Office, PO Box 10812, Birmingham, AL 35202-0812. Checks should be made payable to "Blood Subscriptions."

ASH Members should send their change-of-address information to the ASH Membership Department, 1900 M Street, NW, Suite 200, Washington, DC 20036.

All change-of-address notices should be sent at least 6 weeks before the first issue is to be mailed to the new address. Provide both old and new addresses.

Claims: Claims will be honored if received within 3 months of the month of issue. A maximum of 3 claims per subscription per calendar year will be honored.

Internet

Blood Home Page: www.bloodjournal.org.

ASH Home Page: www.hematology.org.

Manuscript Submission: blood.manuscriptcentral.com.

Copyright

Copyright © 2003 by The American Society of Hematology. All rights reserved. No part of this publication may be reproduced (see exception below), stored in a retrieval system, translated, or transmitted in any form or by any means now or hereafter known, electronic or mechanical, without permission in writing from the Publisher, The American Society of Hematology. Address for correspondence: Blood Publishing Office, 1900 M Street, NW, Suite 200, Washington, DC 20036. For further information on rights and permissions, visit us online at www.bloodjournal.org/misc/rights.shtml.

The copyright owner consents that copies of articles may be made for personal or internal use, or for the personal or internal use of specific clients, for those registered with the Copyright Clearance Center, Inc (222 Rosewood Drive, Danvers, MA 01923; (978) 750-8400; www.copyright.com). This consent is given on the condition that the copier pay the stated per-copy fees through the Copyright Clearance Center, Inc, for copying beyond that permitted by Sections 107 and 108 of the US Copyright Law (Fair Use). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. For those kinds of purposes, permission must be sought from the Publisher (see above).

Advertising representation

To place orders for product advertisements, classifieds, or commercial reprints, contact Bill Scully, Cunningham Associates, 180 Old Tappan Road, Old Tappan, NJ 07675. Telephone: 201-767-4170; fax: 201-767-8065; e-mail: bscully@cunnasso.com.

Disclaimer

The ideas and opinions expressed in *Blood* do not necessarily reflect those of The American Society of Hematology or the Editors of *Blood*. Publication of an advertisement or other product mention in *Blood* should not be construed as an endorsement of the product or the manufacturer's claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The American Society of Hematology does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on his or her independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient.

Indexing & abstracting

Blood is indexed and abstracted by Index Medicus, Excerpta Medica, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, SCISEARCH, Automatic Subject Citation Alert, ISI/BIOMED, and BIOSIS.

COVER FIGURE

Skyline from Coronado, San Diego, California. Photo courtesy of Getty Images.

INTRODUCTORY INFORMATION

- 2 Leaders of the society since its founding
- 3 Current society leadership
- 4 Standing committees
- 6 Scientific subcommittees
- 8 Recipients of awards
- 9 Reviewers of abstracts
- 10 Acknowledgements
- 11 Future annual meeting sites
- 11 ASH headquarters office staff
- 12 General information
- 24 San Diego Convention Center maps
- 27 Master schedule

INVITED SPEAKER SESSIONS

- 35 Special lectures
- 39 Saturday/Sunday schedule at a glance
- 40 Education program
- 60 Scientific committee program
- 85 Meet-the-expert breakfast sessions
- 88 2003 invited speaker index
- 94 2003 invited speaker disclosure index

PLENARY SESSION

- Sunday, December 7, 2003, 1:15 pm-3:30 pm**
- 103 Plenary session I

SIMULTANEOUS SESSIONS

- Sunday, December 7, 2003, 4:15 pm-5:45 pm**
- 104 The erythrocyte membrane and cytoskeleton
 - 104 Granulocytes, monocytes and macrophages I
 - 105 Vascular wall biology
 - 105 Molecular mechanisms of altered platelet production and function
 - 106 Cell biology and animal models
 - 106 New anticoagulant trials
 - 107 Signaling: in vivo hematopoiesis and lineage specification
 - 107 Hematopoietic microenvironment I
 - 108 Strategies for overcoming drug resistance
 - 108 Immature acute leukemia: the AML/ALL interface
 - 109 Molecular biology of acute myeloid leukemia

CONTENTS (continued)

110	Chemotherapy/rituximab combinations and radioimmunotherapy
111	Chronic myelogenous leukemia: new treatment strategies/molecular monitoring
111	Myeloproliferative disorders: treatment
112	CLL: ZAP-70/mutational status
112	Genetics of multiple myeloma
113	Experimental transplantation: engraftment
113	Cell processing: mobilization I
114	Immunotherapy
114	Autologous transplantation: multiple myeloma

Monday, December 8, 2003, 7:30 am-9:00 am

115	Sickle cell disease: novel therapies
115	Thalassemia and globin gene regulation I
116	Granulocytes, monocytes and macrophages II
116	Molecular mechanisms of lymphoid development
117	Platelet adhesion
117	Hemophilia
118	Pathophysiology of thrombosis: experimental
118	Thrombosis risk and management
119	Transfusion medicine I
119	Regulation of gene transcription I
120	Hematopoietic microenvironment II
120	Disordered gene expression in hematologic malignancy I
121	Minimal residual disease and diagnostic markers in acute leukemia
121	Acute leukemia: new agents
122	Molecular cytogenetics and animal models
122	Rituximab and biologic combinations
123	Chronic myelogenous leukemia: resistance to imatinib
123	CLL: therapy I
124	Multiple myeloma: developmental therapeutics
124	Experimental transplantation: regimens
125	Nonmyeloablative transplantation
125	Myeloablative matched related donor transplantation

Monday, December 8, 2003, 11:00 am-12:30 pm

126	Sickle hemoglobinopathies: cellular interactions and pathophysiology
126	Granulocytes, monocytes and macrophages III
127	T cell signaling
127	Immune thrombocytopenias
128	Factor V and factor VIII
128	Von Willebrand disease
129	Pathophysiology of thrombosis: mechanisms
129	Transfusion medicine II
130	Regulation of HSC self-renewal
130	Molecular pharmacology and drug resistance of AML
131	Diagnostic markers in AML
131	Treatment and prognosis of acute myeloid leukemia
132	Clinicopathologic and molecular factors impacting prognosis
132	Non-Hodgkin lymphoma: treatment I
133	Vaccine and dendritic cell-based therapies
133	Myeloproliferative disorders: molecular pathogenesis
134	CLL: therapy II
134	Biology of multiple myeloma
135	Experimental transplantation: basic biology
135	Cell processing: mobilization II
136	Secondary malignancy and late complications after transplantation
136	Autologous transplantation: amyloidosis and Hodgkin's disease

Monday, December 8, 2003, 1:30 pm-3:00 pm

137	Sickle cell disease: clinical correlations
137	Thalassemia and globin gene regulation II
138	Immunodeficiency including HIV infection

139	Acquired thrombocytopenias due to HIV, drugs and TTP
139	Coagulation proteases
140	Coagulation disorders
140	Transcriptional regulators of hematopoietic stem cells
141	Regulation of gene transcription II
141	Signaling in hematopoietic cells
142	Oncogenes and tumor suppressors in B cell malignancies
142	Molecular pharmacology: drug resistance—novel agents and potential targets
143	Advances in acute myeloid and lymphoblastic leukemias
143	Acute promyelocytic leukemia
144	Non-Hodgkin lymphoma: treatment II—adult and pediatric
144	Myelodysplastic syndromes: biologic investigations
145	Myeloproliferative disorders: treatment and biology
145	Novel approaches to multiple myeloma therapy
146	GVHD biology
146	Chronic gvhd and recurrent malignancy after transplantation
147	Allogeneic mismatched or unrelated donor transplantation: KIR and graft manipulation
147	Gene therapy: clinical results

Monday, December 8, 2003, 3:30 pm-5:30 pm

148	Iron and heme metabolism
148	Erythropoiesis I
149	Platelet adhesion receptors
149	Inhibitors of coagulation
150	Antithrombotic therapy
150	Hematopoietic development
151	Signaling: survival and cycling
151	Disordered gene expression in hematologic malignancy II
152	Gene expression profiling in acute leukemia
152	Acute myeloid leukemia
153	Genomic and proteomic profiling
154	Lymphoma: new agents
155	Chronic myelogenous leukemia: imatinib, clinical results
156	Myelodysplastic syndromes: clinical investigations
157	CLL biology I
158	Experimental therapy in multiple myeloma
158	Modulation of GVHD and GVL/GVT effects
159	Transplantation regimen toxicities and engraftment I
160	Infections: complications
160	Non-myeloablative matched related donor transplantation
161	Gene transfer: biology and marking studies I
162	Health services research: methodology

Tuesday, December 9, 2003, 8:00 am-11:00 am

163	Erythropoiesis II
163	Platelet activation and thrombus formation
164	Pathophysiology of thrombosis: risk factors
164	Signaling in stem and progenitor cells
165	Stem cell plasticity
165	Chromosomal rearrangements
166	Disordered gene expression in hematologic malignancy III
166	Mechanisms of leukemogenesis in AML
167	Acute lymphoblastic leukemia I
168	Acute lymphoblastic leukemia II
169	Molecular pathogenesis of lymphoma
169	Chronic myelogenous leukemia: signal transduction/gene expression
170	CLL: biology II
170	Myeloma microenvironment
171	Therapeutics for plasma cell dyscrasia
172	Cell processing: selection, expansion, purging and depletion
172	Transplantation regimen toxicities and engraftment II

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.